The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece.
The company has developed a 6-month buprenorphine implant for the treatment of opioid addiction – the 1st device of its kind to be approved by the FDA.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn pulls the plug on $150m IPO, citing market conditions appeared first on MassDevice.
from MassDevice http://ift.tt/2jL1R9J
Cap comentari:
Publica un comentari a l'entrada